AbstractIrisin, an emerging adipokine, has been involved in the pathogenesis of type 2
diabetes mellitus (T2DM). However, previous studies evaluating the association
between irisin and diabetic nephropathy (DN) showed inconsistent results. We
performed a meta-analysis to evaluate the above association. Matched
case-control studies evaluating the difference of serum irisin between T2DM
patients with and without DN were identified via systematic search of PubMed,
Embase, Cochranes’ Library, China National Knowledge Infrastructure, and
WanFang databases from inception to December 5, 2020. A random-effects model or
a fixed-effects model was used to pool the results according to the
heterogeneity. Overall, thirteen matched case-control studies including 1735
T2DM patients were included. Results of meta-analysis showed that compared to
T2DM patients with normoalbuminuria, those with microalbuminuria [10 studies,
standard mean difference (SMD): 1.12, 95% confidence interval (CI):
0.48–1.77, p<0.001; I2=94%] and
macroalbuminuria (10 studies, SMD: 1.86, 95% CI: 0.93–2.79,
p<0.001; I2=97%) had significantly lower
serum irisin. Besides, the serum level of irisin was significantly lower in T2DM
patients with macroalbuminuria than those with microalbuminuria (10 studies,
SMD: 0.91, 95% CI: 0.44–1.38, p<0.001;
I2=90%). In addition, patients with estimated
glomerular infiltration rate (eGFR)<60 ml/min 1.73 m2
had lower serum irisin compared to those with eGFR≥60 ml/min
1.73 m2 (4 studies, SMD: 0.89, 95% CI: 0.32–1.46,
p=0.002; I2=91%). In conclusion, serum irisin
may be associated with albuminuria and reduced eGFR in T2DM patients.
Association of Adiponectin SNP+45 and SNP+276 with Type 2 Diabetes in Han Chinese Populations: A Meta-Analysis of 26 Case-Control Studies